Alaunos Therapeutics, Inc.
NASDAQ:TCRT
Overview | Financials
Company Name | Alaunos Therapeutics, Inc. |
Symbol | TCRT |
Currency | USD |
Price | 1.84 |
Market Cap | 2,946,300 |
Dividend Yield | 0% |
52-week-range | 1.63 - 33 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Kevin S. Boyle Sr. |
Website | https://www.alaunos.com |
An error occurred while fetching data.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD